Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Fixed-sequence, 5-part, Drug-drug Interaction Study of Tucatinib to Evaluate the Effects of CYP3A4 and CYP2C8 Inhibition and Induction on the Pharmacokinetics of Tucatinib and to Evaluate the Effects of Tucatinib on the Pharmacokinetics of Substrates of CYP3A4, CYP2C8, CYP2C9, and P-glycoprotein in Healthy Male and Female Subjects
Conditions
Interventions
tucatinib
itraconazole
+6 more
Locations
2
United States
Covance Clinical Research Unit
Daytona Beach, Florida, United States
Covance Clinical Research Unit
Dallas, Texas, United States
Start Date
September 17, 2018
Primary Completion Date
December 21, 2018
Completion Date
December 28, 2018
Last Updated
December 18, 2019
NCT06682325
NCT07330531
NCT07017335
NCT04487145
NCT02174822
NCT04459585
Lead Sponsor
Seagen Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions